Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cushing Syndrome II: Pathophysiology01:19

Cushing Syndrome II: Pathophysiology

Cortisol production is normally governed by the hypothalamic–pituitary–adrenal (HPA) axis, which maintains hormonal balance through tightly regulated feedback mechanisms. Disruption of this regulatory system is central to the development of Cushing syndrome, whether the excess cortisol originates from external medications or internal pathology. Persistent cortisol elevation alters metabolism, immune function, and endocrine signaling, producing the characteristic clinical features of the...
Cushing Syndrome I: Introduction01:26

Cushing Syndrome I: Introduction

Cushing syndrome refers to the collection of clinical manifestations that arise when tissues are exposed to excessive amounts of cortisol or cortisol-like medications over an extended period. Cortisol, a glucocorticoid produced by the adrenal cortex, regulates metabolism, immune responses, and the body’s adaptation to stress. When its concentration remains chronically elevated, these physiological pathways become dysregulated, resulting in the characteristic features of the syndrome.Exogenous...
Graves Disease II: Pathophysiology01:24

Graves Disease II: Pathophysiology

Graves’ disease is an autoimmune disorder characterized by the production of thyroid-stimulating immunoglobulins (TSI) that activate TSH receptors, leading to excessive synthesis and release of thyroid hormones (T3 and T4) and resulting in hyperthyroidism.Among all causes of hyperthyroidism, Graves’ disease is the most common and can happen at any age, though it is more frequent in women. It produces a hypermetabolic state with features such as weight loss, tachycardia, tremor, and heat...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Adrenal Gland Disorders01:27

Adrenal Gland Disorders

Adrenal gland disorders manifest when the production of adrenal hormones deviates from the norm, resulting in either excessive or insufficient concentrations.
Adrenal insufficiency, characterized by insufficient cortisol and aldosterone production, leads to conditions like Addison's disease. This disorder, affecting the adrenal cortex, exhibits symptoms such as skin bronzing, dehydration, low blood pressure, fatigue, and weight loss. Congenital adrenal hyperplasia, a genetic ailment causing...
Hyperthyroidism I: Introduction01:25

Hyperthyroidism I: Introduction

Hyperthyroidism is a type of thyrotoxicosis characterized by the thyroid gland's overproduction of the thyroid hormones triiodothyronine (T3) and thyroxine (T4). This hormone excess increases the basal metabolic rate and enhances sensitivity to catecholamines.DiagnosisDiagnosis is based on clinical features and biochemical testing. It typically shows suppressed thyroid-stimulating hormone (TSH) levels below 0.4 mIU/L, with elevated free T3 and/or T4. Additional tests, including thyroid...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Management-specific outcome evaluation of pituitary apoplexy; conservative and surgical approach.

Pituitary·2026
Same author

EndoBridge 2024: pearls and highlights.

Hormones (Athens, Greece)·2025
Same author

Antiseizure medication in patients with meningioma: a retrospective cohort study on the long-term impact on depression, anxiety and neurocognitive functioning.

Journal of neuro-oncology·2025
Same author

Consensus and controversies about diagnosing GH deficiency: a Delphi survey by the GH research society.

Pituitary·2025
Same author

Medical management pathways for Cushing's disease in pituitary tumors centers of excellence (PTCOEs).

Pituitary·2025
Same author

Cyclophosphamide is not associated with clinically relevant late pulmonary dysfunction in Dutch survivors of childhood cancer - The DCCSS-LATER 2 PULM sub-study.

Respiratory medicine·2025

Related Experiment Video

Updated: May 25, 2026

Endoscopic Endonasal Trans-sphenoidal Approach: Minimally Invasive Surgery for Pituitary Adenomas
07:43

Endoscopic Endonasal Trans-sphenoidal Approach: Minimally Invasive Surgery for Pituitary Adenomas

Published on: January 17, 2018

What is active acromegaly and which parameters do we have?

S J C M M Neggers1, N R Biermasz, A J van der Lely

  • 1Department of Medicine, Section Endocrinology, Erasmus University Medical Center Rotterdam, CA Rotterdam, The Netherlands. s.neggers@erasmusmc.nl

Clinical Endocrinology
|January 25, 2012
PubMed
Summary

Disease activity in acromegaly is assessed using growth hormone (GH) and insulin-like growth factor 1 (IGF1) levels. These markers are crucial for monitoring treatment response and predicting patient prognosis, including mortality risk.

More Related Videos

Measurement of Dynamic Scapular Kinematics Using an Acromion Marker Cluster to Minimize Skin Movement Artifact
10:07

Measurement of Dynamic Scapular Kinematics Using an Acromion Marker Cluster to Minimize Skin Movement Artifact

Published on: February 10, 2015

Midface Hypoplasia and Cranial Base Morphology in Syndromic Craniosynostosis: A Comparative Analysis Study Using a Predictive Regression Model
08:03

Midface Hypoplasia and Cranial Base Morphology in Syndromic Craniosynostosis: A Comparative Analysis Study Using a Predictive Regression Model

Published on: November 4, 2025

Related Experiment Videos

Last Updated: May 25, 2026

Endoscopic Endonasal Trans-sphenoidal Approach: Minimally Invasive Surgery for Pituitary Adenomas
07:43

Endoscopic Endonasal Trans-sphenoidal Approach: Minimally Invasive Surgery for Pituitary Adenomas

Published on: January 17, 2018

Measurement of Dynamic Scapular Kinematics Using an Acromion Marker Cluster to Minimize Skin Movement Artifact
10:07

Measurement of Dynamic Scapular Kinematics Using an Acromion Marker Cluster to Minimize Skin Movement Artifact

Published on: February 10, 2015

Midface Hypoplasia and Cranial Base Morphology in Syndromic Craniosynostosis: A Comparative Analysis Study Using a Predictive Regression Model
08:03

Midface Hypoplasia and Cranial Base Morphology in Syndromic Craniosynostosis: A Comparative Analysis Study Using a Predictive Regression Model

Published on: November 4, 2025

Area of Science:

  • Endocrinology
  • Metabolic Diseases
  • Clinical Biochemistry

Background:

  • Acromegaly, a disorder of excess growth hormone (GH), requires effective monitoring of disease activity.
  • Assessing treatment efficacy and patient prognosis is essential for managing acromegaly.
  • Biochemical markers play a pivotal role in evaluating disease status and outcomes.

Purpose of the Study:

  • To review and discuss the various parameters available for assessing disease activity in acromegaly.
  • To highlight the significance of biochemical markers in acromegaly management.
  • To provide an overview of current methods for monitoring acromegaly.

Main Methods:

  • Literature review of studies on acromegaly disease activity assessment.
  • Analysis of biochemical markers, specifically growth hormone (GH) and insulin-like growth factor 1 (IGF1).
  • Discussion of the association between GH and IGF1 levels and patient prognosis, including mortality.

Main Results:

  • Growth hormone (GH) and insulin-like growth factor 1 (IGF1) concentrations are the primary biochemical markers for assessing acromegaly activity.
  • These markers are integral to evaluating the response to therapeutic interventions.
  • Elevated GH and IGF1 levels are linked to increased mortality risk in acromegaly patients.

Conclusions:

  • The review consolidates current knowledge on acromegaly disease activity assessment.
  • Growth hormone (GH) and insulin-like growth factor 1 (IGF1) are indispensable tools for monitoring acromegaly.
  • Accurate assessment of disease activity is critical for improving patient outcomes and survival in acromegaly.